European Medicine Agency to review GSK's chronic hepatitis B treatment
(Alliance News) - GSK PLC on Friday said the European Medicines Agency has accepted for review its investigational chronic hepatitis B treatment, bepirovirsen. Read More
| Price | 2,049.00p on 27-03-2026 at 19:40:07 |
|---|---|
| Change | 2.00p 0.1% |
| Buy | 2,043.00p |
| Sell | 2,042.00p |
| Last Trade: | Sell 4,459.00 at 2,049.00p |
| Day's Volume: | 6,240,777 |
| Last Close: | 2,049.00p |
| Open: | 2,041.00p |
| ISIN: | GB00BN7SWP63 |
| Day's Range | 2,023.00p - 2,060.00p |
| 52wk Range: | 1,242.50p - 2,282.00p |
| Market Capitalisation: | £81.94b |
| VWAP: | 2,044.51465p |
| Shares in Issue: | 4.00b |
Glaxosmithkline (GSK) Latest Trades |
||||
| Buy/Sell | Volume | Trade Prc | Trade Type | Trade Time |
|---|---|---|---|---|
| Sell* | 4,459 | 2,049.00p | SI Trade Suspected SELL Trade |
16:49:04 - 27-Mar-26 |
| Buy* | 57,163 | 2,049.00p | SI Trade Negotiated Trade |
16:37:06 - 27-Mar-26 |
| Buy* | 4,548 | 2,049.00p | Automatic Execution |
16:37:01 - 27-Mar-26 |
| Buy* | 7,560 | 2,049.00p | Automatic Execution |
16:37:01 - 27-Mar-26 |
| Buy* | 264 | 2,049.00p | Automatic Execution |
16:37:01 - 27-Mar-26 |
| Buy* | 1,518 | 2,043.00p | Automatic Execution |
16:29:44 - 27-Mar-26 |
| Buy* | 2 | 2,043.00p | Automatic Execution |
16:29:44 - 27-Mar-26 |
| Buy* | 267 | 2,043.00p | Automatic Execution |
16:29:44 - 27-Mar-26 |
| Unknown* | 0 | 2,043.00p | SI Trade |
16:29:42 - 27-Mar-26 |
| Unknown* | 0 | 2,043.00p | SI Trade |
16:29:34 - 27-Mar-26 |
Glaxosmithkline (GSK) Regulatory News |
||
| Date | Source | Headline |
|---|---|---|
| 27th Mar 2026 7:00 am | RNS | Bepirovirsen accepted for review by the EMA |
| 27th Mar 2026 7:00 am | RNS | Transaction in Own Shares |
| 26th Mar 2026 7:00 am | RNS | Transaction in Own Shares |
| 25th Mar 2026 3:30 pm | RNS | Director/PDMR Shareholding |
| 25th Mar 2026 1:00 pm | RNS | Notice of AGM |
| 25th Mar 2026 7:00 am | RNS | Transaction in Own Shares |
| 24th Mar 2026 7:00 am | RNS | Transaction in Own Shares |
| 23rd Mar 2026 3:30 pm | RNS | Director/PDMR Shareholding |
| 23rd Mar 2026 3:00 pm | RNS | Admission to Trading |
| 23rd Mar 2026 7:00 am | RNS | GSK Lung Cancer ADC Gets Japan Orphan Drug Status |